» Articles » PMID: 36541483

The Oncogenic Driving Force of CD30 Signaling-induced Chromosomal Instability in Adult T-cell Leukemia/lymphoma

Overview
Journal Cancer Sci
Specialty Oncology
Date 2022 Dec 21
PMID 36541483
Authors
Affiliations
Soon will be listed here.
Abstract

Adult T-cell leukemia/lymphoma (ATL) develops via stepwise accumulation of gene mutations and chromosome aberrations. However, the molecular mechanisms underlying this tumorigenic process are poorly understood. We previously reported the presence of a biological link between the expression of CD30, which serves as a marker for ATL progression, and the actively proliferating fraction of human T-cell leukemia virus type 1 (HTLV-1)-infected cells that display polylobulation. Here, we demonstrated that CD30 signaling induced chromosomal instability with clonal expansion through DNA double-strand breaks (DSBs) via an increase of intracellular reactive oxygen species. CD30 ATL cells were composed of subclones with additional genomic aberrations compared with CD30 ATL cells in ATL patients. Furthermore, we found an accumulation of copy number loss of DSB repair-related genes as the disease progressed. Taken together, CD30 expression on ATL cells appears to be correlated with genomic instability, suggesting that CD30 signaling is one of the oncogenic factors of ATL progression with clonal evolution. This study provides new insight into the biological roles of CD30 signaling and could improve our understanding of tumorigenic processes of HTLV-1-infected cells.

Citing Articles

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.

Li Z, Guo W, Bai O Front Oncol. 2024; 13:1301437.

PMID: 38188299 PMC: 10767573. DOI: 10.3389/fonc.2023.1301437.


CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma.

Nakashima M, Uchimaru K Int J Mol Sci. 2023; 24(10).

PMID: 37240076 PMC: 10218159. DOI: 10.3390/ijms24108731.


The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia/lymphoma.

Nakashima M, Utsunomiya A, Watanabe T, Horie R, Uchimaru K Cancer Sci. 2022; 114(4):1556-1568.

PMID: 36541483 PMC: 10067402. DOI: 10.1111/cas.15706.

References
1.
Shimoyama M . Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79(3):428-37. DOI: 10.1111/j.1365-2141.1991.tb08051.x. View

2.
Iqbal J, Kucuk C, Deleeuw R, Srivastava G, Tam W, Geng H . Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009; 23(6):1139-51. DOI: 10.1038/leu.2009.3. View

3.
Dunnill C, Ibraheem K, Mohamed A, Southgate J, Georgopoulos N . A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis. Oncogene. 2016; 36(18):2515-2528. PMC: 5422712. DOI: 10.1038/onc.2016.401. View

4.
Gillis S, Roth A . PyClone-VI: scalable inference of clonal population structures using whole genome data. BMC Bioinformatics. 2020; 21(1):571. PMC: 7730797. DOI: 10.1186/s12859-020-03919-2. View

5.
Oka S, Ono K, Nohgawa M . Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. Anticancer Drugs. 2020; 31(5):536-539. DOI: 10.1097/CAD.0000000000000895. View